Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of modification of postsynaptic structure. [GOC:dos]
The regulation of modification of postsynaptic structure is a complex and dynamic process that involves the coordinated interplay of multiple signaling pathways, molecular components, and cellular processes. It is crucial for maintaining synaptic plasticity, which is the ability of synapses to strengthen or weaken in response to neuronal activity. This process is essential for learning, memory, and other cognitive functions.
**Key aspects of regulation of modification of postsynaptic structure:**
1. **Signal transduction:**
* **Neurotransmitter release:** Upon neuronal activation, neurotransmitters are released from the presynaptic terminal and bind to receptors on the postsynaptic membrane.
* **Activation of intracellular signaling pathways:** This binding triggers a cascade of intracellular signaling events, involving kinases, phosphatases, and second messengers like cAMP, Ca2+, and IP3.
* **Regulation of gene expression:** These signaling pathways can activate or repress gene expression, leading to changes in the synthesis and trafficking of postsynaptic proteins.
2. **Scaffolding and anchoring proteins:**
* **Postsynaptic density (PSD):** A dense protein network at the postsynaptic membrane, acting as a scaffold for receptors, signaling molecules, and other structural components.
* **PSD-95:** A key scaffold protein that interacts with glutamate receptors, ion channels, and signaling molecules, contributing to the assembly and stability of the PSD.
* **Other scaffolding proteins:** Many other proteins like Shank, GKAP, and Homer contribute to the structural organization of the PSD and regulate the interactions of various signaling molecules.
3. **Synaptic receptors:**
* **Glutamate receptors (AMPA, NMDA):** The primary excitatory neurotransmitter receptors in the brain, their trafficking, phosphorylation, and clustering at the synapse play a crucial role in synaptic plasticity.
* **Other receptors:** Other receptors like GABA receptors and acetylcholine receptors also undergo modifications and contribute to synaptic function.
4. **Structural components:**
* **Actin cytoskeleton:** The cytoskeleton provides structural support and plays a role in the movement and localization of synaptic components.
* **Adhesion molecules:** Cell adhesion molecules like cadherins and nectins contribute to the stability and formation of synaptic connections.
5. **Protein turnover:**
* **Protein synthesis and degradation:** The balance between protein synthesis and degradation is essential for regulating the levels of postsynaptic proteins and adapting to changing synaptic activity.
* **Ubiquitin-proteasome system:** This system targets proteins for degradation, contributing to the removal of unnecessary or damaged proteins from the synapse.
6. **Cellular processes:**
* **Microglia:** These immune cells in the brain can engulf and remove synaptic components, contributing to the dynamic remodeling of synapses.
* **Astrocytes:** These glial cells support synaptic function and provide metabolic and structural support. They can also release signaling molecules that influence synaptic plasticity.
**Consequences of dysregulation:**
* **Neurological disorders:** Disruptions in the regulation of postsynaptic structure are linked to a variety of neurological disorders, including Alzheimer's disease, autism spectrum disorder, and schizophrenia.
* **Cognitive impairment:** Dysregulation of synaptic plasticity leads to difficulties in learning, memory, and other cognitive functions.
The intricate regulation of modification of postsynaptic structure is a critical aspect of neuronal function, ensuring adaptable and efficient communication between neurons.'
"
Protein | Definition | Taxonomy |
---|---|---|
Egl nine homolog 1 | An egl nine homolog 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9GZT9] | Homo sapiens (human) |
Transforming protein RhoA | A GTP-binding protein RhoA that is encoded in the genome of human. [PRO:CNA, UniProtKB:P61586] | Homo sapiens (human) |
Cell division control protein 42 homolog | A cell division control protein 42 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P60953] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
alpha-ketoglutaric acid | 2-oxoglutaric acid : An oxo dicarboxylic acid that consists of glutaric acid bearing an oxo substituent at position 2. It is an intermediate metabolite in Krebs cycle. | oxo dicarboxylic acid | fundamental metabolite |
succinic acid | succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle. Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) | alpha,omega-dicarboxylic acid; C4-dicarboxylic acid | anti-ulcer drug; fundamental metabolite; micronutrient; nutraceutical; radiation protective agent |
isocitric acid | isocitric acid : A tricarboxylic acid that is propan-1-ol with a hydrogen at each of the 3 carbon positions replaced by a carboxy group. isocitric acid: RN given refers to unlabeled parent cpd | secondary alcohol; tricarboxylic acid | fundamental metabolite |
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
ketorolac | 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively. ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed) | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
succinylacetone | 4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia. succinylacetone: inhibitor of heme biosynthesis | beta-diketone; dioxo monocarboxylic acid | human metabolite |
2,5-pyridinedicarboxylic acid | 2,5-Pyridinedicarboxylic acid: RN given refers to parent cpd isocinchomeronic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 5. | pyridinedicarboxylic acid | |
glycyrrhetinic acid | cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid | immunomodulator; plant metabolite | |
2,4-pyridinedicarboxylic acid | lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4. | pyridinedicarboxylic acid | |
oleanolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | plant metabolite | |
daminozide | daminozide: induces tumors | straight-chain fatty acid | |
ursolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | geroprotector; plant metabolite | |
betulinic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite | |
sanguinarine chloride | |||
chelerythrine chloride | |||
maslinic acid | (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria | dihydroxy monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite |
fumaric acid | fumaric acid : A butenedioic acid in which the C=C double bond has E geometry. It is an intermediate metabolite in the citric acid cycle. fumaric acid: see also record for ferrous fumarate; use FUMARATES for general fumaric acid esters | butenedioic acid | food acidity regulator; fundamental metabolite; geroprotector |
5-carboxy-8-hydroxyquinoline | 5-carboxy-8-hydroxyquinoline: a JmjC histone demethylase inhibitor; structure in first source | quinolines | |
2-[[benzamido(sulfanylidene)methyl]amino]-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic acid | CID1067700: a pan-GTPase inhibitor; structure in first source | thienopyran | |
oxalylglycine | N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes. oxalylglycine: structure given in first source | amino dicarboxylic acid; N-acylglycine | EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor |
y 27632, dihydrochloride, (4(r)-trans)-isomer | |||
secramine a | secramine A: inhibits VSVG transport from the Golgi to the plasma membrane; also inhibits Cdc42-dependent cell functions; structure in first source | ||
fg-4592 | roxadustat : An N-acylglycine resulting from the formal condensation of the amino group of glycine with the carboxy group of 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylic acid. It is an inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH). roxadustat: structure in first source | aromatic ether; isoquinolines; N-acylglycine | EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor; EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor |
jnj 42041935 | |||
ascorbic acid | Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms. | ascorbic acid; vitamin C | coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent |
2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid | quinolines | ||
bay 85-3934 | |||
ccg-203971 | |||
gsk1278863 | daprodustat : A member of the class of barbiturates that is barbituric acid substituted by cyclohexyl groups at positions 1 and 3, and by a (carboxymethyl)aminocarbonyl group at position 5. It is an inhibitor of hypoxia-inducible factor prolyl hydroxylase developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease. GSK1278863: a HIF prolyl hydroxylase inhibitor |